Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum - Summary - MDSpire

Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum

  • By

  • Andrea Mastrangelo

  • Angela Mammana

  • Sara Hall

  • Erik Stomrud

  • Corrado Zenesini

  • Marcello Rossi

  • Shorena Janelidze

  • Alice Ticca

  • Sebastian Palmqvist

  • Franco Magliocchetti

  • Simone Baiardi

  • Niklas Mattsson-Carlgren

  • Oskar Hansson

  • Piero Parchi

  • December 17, 2024

  • 0 min

Share

Objective:

To assess baseline α-syn CSF SAA kinetic parameters, their longitudinal variations, and associations with clinical outcomes in a longitudinal cohort of Lewy Body Disorder patients.

Key Findings:
  • 196 individuals showed α-syn seeding activity; 170 remained positive, while 26 converted from negative to positive.
  • LBD-converters had lower Nrep and longer Lag at baseline compared to persistent positives.
  • Nrep increased and Lag decreased longitudinally, particularly in asymptomatic LBD and Parkinson's disease without dementia.
  • Baseline Nrep predicted subsequent dementia appearance in the cohort and Parkinson's subgroup.
Interpretation:

The α-syn SAA parameters Nrep and Lag correlate with LBD stage and dementia development, indicating their potential as biomarkers for monitoring disease progression and guiding treatment decisions.

Limitations:
  • The study is limited to a specific cohort and may not generalize to all Lewy Body Disorder patients.
  • Longitudinal data collection was dependent on participant retention and compliance, which may introduce bias.
Conclusion:

The findings support the use of α-syn SAA kinetic parameters to monitor disease progression and therapeutic response in Lewy Body Disorder, highlighting their potential role in future research.

Original Source(s)

Related Content